This approach has been evidenced using mesothelin-specific CAR-T-cell-derived EVs against breast cancer cells, mediating the killing of tumor cells in vitro and in vivo by the expression of perforin and granzyme B [160]. This evidence concerns the gene GZMB and breast carcinoma.